Guotai Venture Capital
国泰创投
Guotai Venture Capital (国泰创投) is a Chinese venture capital firm that appears in elsewhere's corpus primarily as a co-investor in biotech and AI infrastructure deals. Per BlueRun Ventures materials, it followed on in CAS-Ruiyi's Series A round in early 2023 and was listed among prior investors in the company's Series A+ in late 2024 . The fund's name surfaces in the context of neurological-disease diagnostics and intelligent medical infrastructure, though elsewhere's corpus does not contain a dedicated profile of its founding date, AUM, or full investment strategy.
AI-generated — may contain errors, please verify.
Coverage
CereMediTech Successfully Completes Series A+ Funding Round | BlueRun Ventures
Building the "New Infrastructure" for Diagnosing and Treating Neurological Disorders
CereMediTech Completes Tens of Millions of Yuan in Series A Funding to Advance Intelligent Diagnosis and Treatment Infrastructure for Neurological Diseases | BlueRun Ventures
Intelligent Technology Solutions for Full-Spectrum Neurological Diseases
The New Cross-Disciplinary Investment Species Are Here — AI + Fitness, Pets + Stem Cells, AR + Everything... | FreeS Family Funding News · Vol 12
Looking forward to working alongside more outstanding founders.
